Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases
R Spiera, S Jinich, D Jannat-Khah - Annals of the rheumatic diseases, 2021 - ard.bmj.com
R Spiera, S Jinich, D Jannat-Khah
Annals of the rheumatic diseases, 2021•ard.bmj.comThere is a paucity of data on the effect of antirheumatic drugs on serological responses to
COVID-19 vaccines. Anti-CD20 therapies deplete B-cells, with reconstitution often not
beginning for 6–9 months after infusion, resulting in diminished humoral immune
responsiveness to recall antigens. 1–6 We retrospectively assessed response to COVID-19
vaccination in rheumatic disease patients treated with a variety of antirheumatic medications
including rituximab. A retrospective chart review of adult patients from one rheumatology …
COVID-19 vaccines. Anti-CD20 therapies deplete B-cells, with reconstitution often not
beginning for 6–9 months after infusion, resulting in diminished humoral immune
responsiveness to recall antigens. 1–6 We retrospectively assessed response to COVID-19
vaccination in rheumatic disease patients treated with a variety of antirheumatic medications
including rituximab. A retrospective chart review of adult patients from one rheumatology …
There is a paucity of data on the effect of antirheumatic drugs on serological responses to COVID-19 vaccines. Anti-CD20 therapies deplete B-cells, with reconstitution often not beginning for 6–9 months after infusion, resulting in diminished humoral immune responsiveness to recall antigens. 1–6 We retrospectively assessed response to COVID-19 vaccination in rheumatic disease patients treated with a variety of antirheumatic medications including rituximab.
A retrospective chart review of adult patients from one rheumatology practice who received at least one dose of a COVID-19 vaccine was performed. Data were collected from patients who had a clinic visit from 24 February 2021 to 8 April 2021 and were serologically screened for antibodies to the SARS-CoV-2 Spike protein.
ard.bmj.com
